



4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-0001]

Advisory Committee Renewals

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the renewal of certain FDA advisory committees by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the charters of the committees listed in the following table for an additional 2 years beyond charter expiration date. The new charters will be in effect until the dates of expiration listed in the following table.

DATES: Authority for these committees will expire on the dates indicated in the following table unless the Commissioner formally determines that renewal is in the public interest.

Name of Committee	Date of Expiration
Advisory Committee for Pharmaceutical Science and Clinical Pharmacology	January 22, 2016
Gastrointestinal Drugs Advisory Committee	March 3, 2016
Bone, Reproductive and Urologic Drugs Advisory Committee (formerly Reproductive Health Drugs Advisory Committee)	March 23, 2016 April 5, 2016
Arthritis Advisory Committee	April 25, 2016

Pharmacy Compounding Advisory Committee	May 1, 2016
Anesthetic and Analgesic Drugs Advisory Committee	May 13, 2016
Blood Products Advisory Committee	May 30, 2016
Pulmonary-Allergy Drugs Advisory Committee	May 31, 2016
Drug Safety and Risk Management Advisory Committee	June 2, 2016
Science Advisory Board to the National Center for Toxicological Research	June 4, 2016
Peripheral and Central Nervous System Drugs Advisory Committee	June 4, 2016
Psychopharmacologic Drugs Advisory Committee	June 9, 2016
Transmissible and Spongiform Encephalopathies Advisory Committee	June 26, 2016
Science Board to the Food and Drug Administration	July 9, 2016
Allergenic Products Advisory Committee	

FOR FURTHER INFORMATION CONTACT: Michael Ortwerth, Director, Advisory Committee Oversight and Management Staff, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, 301-443-0572 or 1-800-741-8138.

For further information related to FDA advisory committees please visit us at:

<http://www.fda.gov/AdvisoryCommittees/default.htm>.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: August 19, 2014.

Peter Lurie,

Associate Commissioner for Policy and Planning.

[FR Doc. 2014-20017 Filed 08/22/2014 at 8:45 am; Publication Date: 08/25/2014]